Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $0.88 in the prior trading day, Coherus Oncology Inc (NASDAQ: CHRS) closed at $0.87, down -1.12%. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 0.96 million shares were traded. CHRS stock price reached its highest trading level at $0.9248 during the session, while it also had its lowest trading level at $0.8617.
Ratios:
Our goal is to gain a better understanding of CHRS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 201.27. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 100629840 and an Enterprise Value of 317721088. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.51. Its current Enterprise Value per Revenue stands at 1.167 whereas that against EBITDA is -4.084.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.87, which has changed by -0.34736842 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 3.91%, while the 200-Day Moving Average is calculated to be -15.67%.
Shares Statistics:
The stock has traded on average 1.41M shares per day over the past 3-months and 1611170 shares per day over the last 10 days, according to various share statistics. A total of 115.91M shares are outstanding, with a floating share count of 105.41M. Insiders hold about 9.07% of the company’s shares, while institutions hold 51.02% stake in the company. Shares short for CHRS as of 1752537600 were 31228059 with a Short Ratio of 22.10, compared to 1749772800 on 31942421. Therefore, it implies a Short% of Shares Outstanding of 31228059 and a Short% of Float of 28.01.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
